Edition:
United States

Aeterna Zentaris Inc (AEZS.PH)

AEZS.PH on Philadelphia Stock Exchange

2.92USD
29 Mar 2017
Change (% chg)

$-0.05 (-1.68%)
Prev Close
$2.97
Open
$2.92
Day's High
$2.92
Day's Low
$2.92
Volume
100
Avg. Vol
1,064
52-wk High
$5.45
52-wk Low
$2.35

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris files for common shares stock shelf offering of up to $50 mln
Tuesday, 21 Mar 2017 04:49pm EDT 

Aeterna Zentaris Inc :Aeterna Zentaris Inc- files for common shares stock shelf offering of up to $50 million - sec filing.  Full Article

Aeterna Zentaris qtrly loss per share $0.71
Wednesday, 15 Mar 2017 04:48pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports fourth quarter and full-year 2016 financial and operating results .Aeterna Zentaris Inc - qtrly loss per share $0.71.  Full Article

Aeterna Zentaris announces EMA pediatric committee agreement
Tuesday, 7 Mar 2017 08:30am EST 

Aeterna Zentaris Inc : Aeterna Zentaris announces EMA pediatric committee agreement on the pediatric investigation plan for macrilen(TM) . Aeterna Zentaris Inc- .Aeterna Zentaris - pediatric committee of EMA agreed co may defer conducting pip until after it files a MAA seeking authorization for use of Macrilen.  Full Article

Aeterna Zentaris completes Zoptrex(tm) pivotal Phase 3 clinical trial in advanced endometrial cancer
Monday, 30 Jan 2017 05:30pm EST 

Aeterna Zentaris Inc : Aeterna Zentaris announces completion of Zoptrex(TM) pivotal Phase 3 clinical trial in advanced endometrial cancer; expects to report top-line results in April 2017 . Aeterna Zentaris Inc - Currently expects to lock clinical database and to report top-line results in April 2017 for Phase 3 zoptec with zoptrex .Aeterna Zentaris Inc - Occurrence of 384th death in pivotal phase 3 zoptec study with zoptrex.  Full Article

Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen
Wednesday, 26 Oct 2016 08:00am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen .Aeterna Zentaris - expects to file a new drug application for Macrilen with United States food and drug administration during first half of 2017.  Full Article

Aeterna and Specialised Therapeutics Asia sign exclusive license agreement
Wednesday, 12 Oct 2016 08:00am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive license agreement for the potential marketing of Zoptrex(TM) in Australia and New Zealand . Aeterna Zentaris Inc - company expects to complete phase 3 clinical trial for Zoptrex in 2016 . Aeterna Zentaris Inc - plans to submit a new drug application for Zoptrex(TM) to United States Food And Drug Administration (FDA) in first half of 2017 . Aeterna Zentaris - co to be entitled to receive non-refundable upfront payment in consideration for license to sta of co's IP related to Zoptrex(TM) . Aeterna Zentaris - entitled to non-refundable upfront payment in consideration allso for grant to STA of right to commercialize Zoptrex in territory . Aeterna Zentaris - STA has also agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones . Aeterna zentaris- STA has also agreed to make additional payments to co such as double-digit royalties on future net sales of Zoptrex(TM) in territory . Aeterna Zentaris - STA will be responsible for development, reimbursement, commercialization of product in territory (Australia, New Zealand) .Aeterna Zentaris Inc - supply agreement with STA pursuant to which company will supply zoptrex(TM) to sta for duration of license agreement.  Full Article

Aeterna Zentaris reports Q2 loss per share $0.71
Tuesday, 9 Aug 2016 04:30pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports second quarter 2016 financial and operating results . Q2 loss per share $0.71 .Product development programs on track towards FDA submission in 2017.  Full Article

Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel
Monday, 1 Aug 2016 08:30am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel . Company expects to complete phase 3 clinical trial in Q3 of 2016 . Company and Rafa have also entered into a supply agreement . Entitled to receive a non-refundable upfront payment in consideration for license to Rafa of intellectual property related to Zoptrex .Company will supply Zoptrex to Rafa for duration of license agreement.  Full Article

Aeterna Zentaris, Orient Europharma sign license agreement for Zoptrex
Friday, 1 Jul 2016 08:30am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Orient Europharma Co Ltd sign exclusive license agreement for Zoptrex in Taiwan and Southeast Asia . Co will be entitled to receive non-refundable upfront payment for license to Cyntec of co's intellectual property related to Zoptrex . Company expects to complete Phase 3 clinical trial in Q3 of 2016 for Zoptrex . Cyntec agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones .Company will receive royalties on future net sales of Zoptrex in Taiwan, 9 countries in Southeast Asia.  Full Article

Aeterna Zentaris says IND submission by Sinopharm A-Think
Tuesday, 14 Jun 2016 05:00pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris announces IND submission by Sinopharm A-Think .Sinopharm A-Think pharmaceuticals co submitted IND for Zoptrex to Chinese state food and drug administration.  Full Article

More From Around the Web

BRIEF-Aeterna Zentaris files for common shares stock shelf offering of up to $50 mln

* Aeterna Zentaris Inc- files for common shares stock shelf offering of up to $50 million - sec filing Source text (http://bit.ly/2mMXM6t) Further company coverage: